Phase III trial comparing neoadjuvant mFOLFIRINOX versus PAXG in stage I-III PDAC

29 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the results of a randomized Phase III trial (NCT04793932) comparing the modified FOLFIRINOX regimen with the PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC), highlighting that the PAXG regimen significantly prolongs event-free survival (EFS), with a EFS increase of almost six months and a three-year EFS rate more than doubling from 13% to 31%. Prof. Reni suggests that this new regimen may be considered a new standard for PDAC, despite concerns about overall survival (OS) data, and proposes that a maintenance therapy trial after surgery could be a promising strategy to further improve three-year EFS rates. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo